CALCA and multiminicore myopathy: Our real‐world data suggest that the guideline suggestion of considering a treatment break after a year of treatment with CGRP‐monoclonal antibodies results in a significant worsening of MMD, MHD, AMD, intensity of attacks, length of attacks as well as concomitant symptoms in most migraine patients when compared to levels at 12 months of CGRP (pathway) mAb treatment.